Treatment of Port Wine Stains and Birthmarks — Procedure Guide, Recovery & Risks | MyMedicPlus

Port wine stains (naevus flammeus, capillary vascular malformations) are congenital vascular birthmarks caused by a somatic mosaic mutation in the GNAQ gene (most commonly R183Q or Q209L), resulting in dysregulated PI3K/mTOR and RAS/MEK/ERK signalling within dermal capillary endothelial cells. This leads to progressive ectasia (dilatation) of superficial dermal capillaries without any tendency to spontaneous involution, in contrast to infantile haemangiomas which involute completely. Port wine stains affect approximately 3 per 1,000 births, appearing at birth as flat, macular, pink-red patches that darken to a deep purple-red over decades, and develop nodular hypertrophy and soft tissue overgrowth in adulthood if untreated. They occur most commonly on the face and neck in a trigeminal distribution; large facial port wine stains in V1 distribution are associated with Sturge-Weber syndrome (ipsilateral leptomeningeal vascular malformation causing epilepsy, glaucoma, and developmental delay) requiring neurological and ophthalmological surveillance. Pulsed dye laser (PDL) is the gold-standard treatment, exploiting selective photothermolysis to target oxyhaemoglobin within ectatic vessels. The earlier treatment is initiated — ideally in infancy — the greater the likelihood of significant lightening or clearance. Current clinical guidelines from BSLS and AAD recommend initiating laser therapy in early infancy to maximise the therapeutic window and minimise long-term psychological impact.

Treatment is recommended beginning in early infancy or childhood (ideally under 2 years of age), when port wine stains are thinner, have fewer ectatic vessels, and respond significantly better to laser therapy than in adults. Younger patients require general anaesthesia for treatment. Facial port wine stains causing disfigurement and associated psychological distress are the primary treatment priority. All infants with facial port wine stains in the trigeminal V1 distribution (forehead, upper eyelid) require ophthalmology assessment for glaucoma and neurology evaluation with MRI brain for Sturge-Weber syndrome. Adults with hypertrophic, nodular, or progressively thickening lesions may require combined laser modalities. Lesions on the central face, lips, and neck respond less favourably than lateral face and trunk lesions. Adults with untreated or partially treated port wine stains — particularly those with hypertrophied, nodular lesions or significant soft tissue overgrowth — may require combined laser therapy and surgical debulking to achieve meaningful improvement.

Pulsed dye laser (PDL) at 585 nm or 595 nm wavelength is the primary treatment modality, exploiting the principle of selective photothermolysis: the 595 nm wavelength is selectively absorbed by oxyhaemoglobin in the ectatic dermal vessels, generating heat that coagulates the vessel wall without damaging the surrounding dermis when pulse duration is matched to the thermal relaxation time of the target vessel (approximately 1-10 ms). Dynamic cooling of the epidermis with a cryogen spray immediately before each laser pulse (Dynamic Cooling Device, DCD) protects the overlying skin from collateral thermal injury. In adults and older children, a topical anaesthetic cream (EMLA — eutectic mixture of local anaesthetics — or LMX4) is applied under occlusion for 45-60 minutes before treatment to reduce discomfort. Infants and young children may require general anaesthesia, particularly for large facial lesions. Treatment sessions are spaced 4-8 weeks apart; the number of sessions required ranges from 6-20 or more depending on lesion characteristics — size, depth, colour intensity, location, and skin phototype. Adjunctive treatments for refractory or deeper vessels include long-pulsed Nd:YAG laser (1064 nm) for deeper and nodular components, alexandrite laser (755 nm), and photodynamic therapy (PDT) with topical aminolaevulinic acid (ALA) or intravenous verteporfin for deeper vascular components unresponsive to surface laser. Topical rapamycin (sirolimus) cream has shown emerging efficacy in facilitating PDL response by inhibiting the mTOR pathway driving vessel proliferation.

PDL achieves clinically significant lightening — defined as greater than 50% colour reduction — in 70-80% of patients completing a full treatment course of 6-12 sessions. Early treatment initiation in infancy or early childhood (before age 2) is associated with the best outcomes, achieving complete or near-complete clearance in 25-40% of cases in published series, because lesions are thinner with fewer ectatic vessels, and the immature skin has less competing background pigmentation. Face lesions (particularly centrofacial and malar distributions) respond better than V3 distribution (jaw, chin, lip) and better than trunk or limb lesions. Lighter pink lesions respond significantly better than dark purple-red lesions; the latter require more sessions and achieve less complete clearance due to deeper and more numerous ectatic vessels. Beyond cosmetic improvement, successful treatment prevents the progressive nodular hypertrophy and soft tissue overgrowth that develops in untreated adults, which is far more difficult to manage. Psychological benefits of early treatment are substantial, with evidence of improved body image, reduced stigmatisation, and better psychosocial development in children treated before school age.

Post-laser purpura (bruising) is an expected treatment endpoint following PDL, representing vessel coagulation; it lasts 7-14 days after each session and indicates adequate energy delivery to the target vessels. Patients must be counselled that purpura is a desired outcome, not a complication. Transient post-inflammatory hyperpigmentation (darkening) occurs in 5-15% of patients, particularly those with Fitzpatrick skin types IV-VI (olive to dark skin), and usually resolves over 3-6 months with strict sun protection and topical agents. Conversely, hypopigmentation (lightening of normal surrounding skin) may result from melanocyte damage at high energy densities; this is generally temporary but may persist for up to 12 months. Scarring is rare with properly performed PDL (under 1%) but becomes more likely when treatment energy is set too high, when skin phototype is not accounted for in parameter selection, or when overlying infection complicates healing. Blistering beyond superficial epidermolysis suggests excessive energy delivery and requires wound care with non-adhesive dressings. Textural change — skin thickening or thinning — may develop with repeated high-energy treatments over the same area. Risk of general anaesthesia applies to paediatric patients treated under sedation or general anaesthesia.

Immediately after laser treatment, the skin is red, swollen, and bruised (purpuric). A thin layer of petrolatum or non-adherent dressing is applied. Ice packs can be used for 15-20 minutes hourly for the first 24 hours to reduce swelling. Topical antibiotic ointment is applied for 5-7 days if blistering occurs. Sun avoidance is essential for 4-6 weeks after each session and SPF 50+ broad-spectrum sunscreen is applied daily thereafter. Sessions are repeated every 6-8 weeks; a typical treatment course spans 2-5 years. Cosmetic camouflage (Dermablend, Covermark) is used between treatment sessions for daytime coverage. Long-term maintenance laser sessions every 1-3 years are often required as treated lesions can slowly redarken over time. Patients with Sturge-Weber syndrome require lifelong neurology and ophthalmology co-management.